Transcutaneous Cervical Vagus Nerve Stimulation Ameliorates Acute Ischemic Injury in Rats

Abstract

Background Direct stimulation of the vagus nerve in the neck via surgically implanted electrodes is protective in animal models of stroke. We sought to determine the safety and efficacy of a non-invasive cervical VNS (nVNS) method using surface electrodes applied to the skin overlying the vagus nerve in the neck in a model of middle cerebral artery occlusion (MCAO). Methods nVNS was initiated variable times after MCAO hour in rats (n=33). Control animals received sham stimulation (n=33). Infarct volume and functional outcome were assessed on day 7. Brains were processed by immunohistochemistry for microglial activation and cytokine levels. The ability of nVNS to activate the nucleus tractus solitarius (NTS) was assessed using c-Fos immunohistochemistry. Results Infarct volume was 43.15±3.36 percent of the contralateral hemisphere (PCH) in control and 28.75±4.22 PCH in nVNS-treated animals (p<0.05). The effect of nVNS on infarct size was consistent when stimulation was initiated up to 4 hours after MCAO. There was no difference in heart rate and blood pressure between control and nVNS-treated animals. The number of c-Fos positive cells was 32.4±10.6 and 6.2±6.3 in the ipsilateral NTS (p<0.05) and 30.4±11.2 and 5.8±4.3 in the contralateral NTS (p<0.05) in nVNS-treated and control animals, respectively. nVNS reduced the number of Iba-1, CD68, and TNF-α positive cells and increased the number of HMGB1 positive cells. Conclusions nVNS inhibits ischemia-induced immune activation and reduces the extent of tissue injury and functional deficit in rats without causing cardiac or hemodynamic adverse effects when initiated up to 4 hours after MCAO.

Targeting neural reflex circuits in immunity to treat kidney disease

“…In addition, a transcutaneous device has been developed that can deliver a proprietary, low-voltage electrical signal to the cervical vagus nerve 64 . In 2016, transcutaneous cervical VNS was reported to protect against cerebral ischaemic injury in rats 65 . In addition, a pilot trial showed that VNS using a gammaCore ® transcutaneous device could downregulate inflammatory cytokine release in healthy individuals 66 .…”

The strange case of the ear and the heart: The auricular vagus nerve and its influence on cardiac control

“…In recent years the major sites of interest for delivering electrical stimulation to the ABVN have been the inner surface of the tragus (Busch et al, 2013;Clancy et al, 2014;Kraus et al, 2013;Stavrakis et al, 2015;Weise et al, 2015;Zhou et al, 2016), the concha (Ay et al, 2015b;Fang et al, 2015;He et al, 2013b;Liu et al, 2013), and the cymba concha (Frangos et al, 2015;Kreuzer et al, 2014). In parallel with these ear studies, a method said to allow non-invasive cervical vagus nerve stimulation through the skin of the neck has also been developed and is under investigation in patients with cluster headache (Nesbitt et al, 2015) and migraine (Barbanti et al, 2015).…”

Non‐invasive transcutaneous auricular vagus nerve stimulation prevents postoperative ileus and endotoxemia in mice

“…Likewise, the electroCore LLC gammaCore device (Basking Ridge, NJ, USA) is a non‐invasive VNS to treat primary headache. Meanwhile, tVNS has been tested in several pilot trials including treatment of migraine depression and epilepsia in humans and in rodent models of epilepsia, stroke and pain relief. However, the effect of tVNS has not been tested in models of peripheral inflammatory diseases for example POI.…”